Toxic fungi behind the ‘Pharaoh's curse' can kill cancer cells
Carnarvon's untimely death, five months later in April 1923, helped spawn the myth of the pharaoh's curse – that anyone who disturbs a mummy's tomb is doomed to misfortune.
Some scientists suspect the real killer, however, was infection by a toxic fungus that lay dormant in the tomb like a booby trap: Aspergillus flavus. Now the fungus is again at the centre of intrigue after researchers in the US crafted the deadly spores into a compound that can kill cancer cells.
In the search for new drugs, scientists have been studying a group of natural molecules called RiPPs (ribosomally synthesised and post-translationally modified peptides).
Many of these tiny proteins have proved toxic to infectious microbes and cancer cells, which is why researchers are on the hunt for new types of RiPPs to test their medical potential.
'We often think of fungi as causing disease or food spoilage, but this is an example of them holding the key to treating diseases.'
Dr Justin Beardsley, University of Sydney
Thousands of these molecules have been found in bacteria but only a few from fungi, which is why researchers from the University of Pennsylvania went looking in Aspergillus.
They found new types of RiPPs with a structure of interlocking rings and tested them against human leukemia cells. Some of the molecules blocked the growth of the cancerous cells.
Scientists then added a fat molecule present in the royal jelly that bees feed their larvae. The fat molecule or 'lipid' helped the cancer-busting RiPPs to infiltrate leukemia cells, and together the experimental combination performed as effectively as two existing leukemia drugs.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Sydney Morning Herald
7 hours ago
- Sydney Morning Herald
Coldplay frontman's warning to fans after ‘kiss cam' controversy
Coldplay frontman Chris Martin has delivered a cheeky warning to fans they may appear on the big screen during the British band's latest US concert at the weekend – just days after 'kiss cam' video from an earlier show went viral because of the reaction of the pair caught on camera. The Jumbotron Song footage was captured at Coldplay's concert during their Music of the Spheres world tour in Foxborough, Massachusetts, on Wednesday evening (Thursday morning AEST), and appeared to show Astronomer CEO Andy Byron and his chief people officer Kristin Cabot cuddling. Realising they were on the big screen, Byron appeared to duck away while Cabot hid her face behind her hands and turned away from the camera. 'Oh, look at these two ... Either they're having an affair or they're very shy,' Martin said, as laughter rang out across the stadium. Both are believed to be married to other people and Byron resigned from his position as CEO of the New York-based $1.5 billion company on Saturday, according to a statement posted on LinkedIn by the company. On Saturday night (local time) at the band's show in Madison Wisconsin, Martin appeared to deliver an oblique nod to the incident while not specifically referring to it as he warmed up the crowd for another round of footage. 'We'd like to say hello to some of you in the crowd,' Martin said, smiling as he strummed his guitar. 'And how we're going to do this is, we're going to use our cameras and we're going to put someone on the big screen. So please if you haven't done your makeup, do your makeup now.'

The Age
7 hours ago
- The Age
Coldplay frontman's warning to fans after ‘kiss cam' controversy
Coldplay frontman Chris Martin has delivered a cheeky warning to fans they may appear on the big screen during the British band's latest US concert at the weekend – just days after 'kiss cam' video from an earlier show went viral because of the reaction of the pair caught on camera. The Jumbotron Song footage was captured at Coldplay's concert during their Music of the Spheres world tour in Foxborough, Massachusetts, on Wednesday evening (Thursday morning AEST), and appeared to show Astronomer CEO Andy Byron and his chief people officer Kristin Cabot cuddling. Realising they were on the big screen, Byron appeared to duck away while Cabot hid her face behind her hands and turned away from the camera. 'Oh, look at these two ... Either they're having an affair or they're very shy,' Martin said, as laughter rang out across the stadium. Both are believed to be married to other people and Byron resigned from his position as CEO of the New York-based $1.5 billion company on Saturday, according to a statement posted on LinkedIn by the company. On Saturday night (local time) at the band's show in Madison Wisconsin, Martin appeared to deliver an oblique nod to the incident while not specifically referring to it as he warmed up the crowd for another round of footage. 'We'd like to say hello to some of you in the crowd,' Martin said, smiling as he strummed his guitar. 'And how we're going to do this is, we're going to use our cameras and we're going to put someone on the big screen. So please if you haven't done your makeup, do your makeup now.'

9 News
8 hours ago
- 9 News
Doctors call for use of spinal cord stimulators to be reconsidered
Your web browser is no longer supported. To improve your experience update it here Australian doctors and health fund providers are calling for the use of spinal cord stimulators to be reconsidered after research revealed one-in-four people are having revision surgery for complications. Spinal cord stimulators have been used to treat chronic pain, including back pain, neck pain, nerve pain, and complex regional pain syndrome. The devices are made up of a small battery pack, which is implanted beneath the skin and attached to electrodes. Pulses of electricity are theoretically supposed to interfere with pain signals coming from the nerves. An image showing what a spinal cord stimulator would look like when inserted into a patient. (iStock) However, a study by leading Australian doctors, published in this week's Medical Journal of Australia , found 23 per cent of patients fitted with the device will go on to need revision surgery for complications within three years. The median cost for the permanent device is nearly $56,000, with some patients' treatment adding up to more than $500,000. "Given the lack of supportive data for their efficacy, and a concerning harms profile, use of spinal cord stimulators for pain control should be reconsidered," the researchers wrote in the journal. Lead author Dr Caitlin Jones, from the University of Sydney's Institute of Musculoskeletal Health, told The Sydney Morning Herald the risk posed by the devices was much greater than the likely benefits. "Patients should know they are taking on a substantial risk, that is exorbitantly expensive, with very little likelihood of any benefit." Private Healthcare Australia, which represents health insurance funds and their 15 million members, has backed the researchers' calls for the use of the devices to be reconsidered. PHA CEO Dr Rachel David said while the Therapeutic Goods Administration (TGA) last year cancelled the registration of some spinal cord stimulators and imposed conditions on others, they were still available and being used on patients. "The regulatory action taken so far has been insufficient. Put simply, if these spinal cord stimulators were new technologies trying to get listed for Medicare funding in Australia, they would be deemed too dangerous," she said. "The Australian Government should ask the Medicare Services Advisory Committee to assess these devices and consider if they meet contemporary standards for listing. If not, the Medicare items and devices should be removed. This would protect patients from unnecessary harm and reduce wasteful expenditure for taxpayers and people with health insurance who are effectively being forced to fund this." At least 90 per cent of spinal cord stimulators are inserted in the private health sector. "Health funds are committed to continuing to fund evidence-based treatments which have demonstrated safety and efficacy in the treatment of chronic pain," David said. The Medical Technology Association of Australia (MTAA), which represents device manufacturers has said the devices are safe and effective. Stimulators were "a demonstrably safe and effective alternative to long-term drug therapies, notably opioids", a spokesman told The Sydney Morning Herald. "[Stimulator] suppliers stand behind the safety, quality and efficacy of our SCS technologies that have demonstrated positive outcomes for patients, which are backed by robust clinical trial data and real-world evidence." health Health Services national Australia Research CONTACT US